Schizophrenia

Volunteer-based biobanks can provide insight into people with less severe forms of illnesses like schizophrenia compared with samples recruited from clinical settings, according to a study published in JAMA Psychiatry.

According to results published in Orthopedics, patients with vs. without psychiatric diagnoses, such as depression, bipolar disorder, anxiety disorder and schizophrenia, had similar clinical outcomes after fracture-related infection.

A Swiss biopharmaceutical company announced its launch with $63 million in Series A financing for research and development of allosteric modulator therapeutics to address underserved neurological disorders.

The FDA has approved Fanapt tablets for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.

Bristol Myers Squibb has completed its acquisition of Karuna Therapeutics, including Karuna’s therapeutic portfolio featuring a novel, investigational muscarinic antipsychotic to treat schizophrenia and Alzheimer’s disease.

While psychedelic use may be associated with fewer psychotic symptoms among adolescents, the link between psychedelics and manic symptoms appears to be associated with genetic vulnerability to schizophrenia or bipolar disorder, data show.

Epidemiological data show women with schizophrenia are 63% more likely to develop CVD during 3.5 years of follow-up compared with those without the condition, with a greater risk observed for women with obesity.

The FDA has declined to approve a new drug application for roluperidone to treat negative symptoms in individuals with schizophrenia.

Quolet Industries has announced the completion of a phase 1 study evaluating a novel, lipid formulation of pure CBD as a potential treatment for various psychiatric and neurologic conditions.